SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NPSP NPS Pharmaceutical
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
363 40 0 NPSP
Emcee:  Jim Langdon Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
288>>SALT LAKE CITY, Feb. 23 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Ituck-2/23/2006
287>>Lilly's Forteo Seen Weighing On NPS Pharmaceuticals Peter Kang, 11.tuck-11/4/2005
286Since NPSP actually sells a couple of things now, we get to watch earnings, hahatuck-11/4/2005
285Another co-promotion deal. With luck, NPS reps will have THREE things to talk ttuck-10/24/2005
284citi/ssb q3 prev: NPS Pharmaceuticals (NPSP, Buy, Speculative) Reporting date:mopgcw-10/10/2005
283<i>Makes you wonder how high that wall between investment bankers and analDewDiligence_on_SI-9/8/2005
282porous, what else?tom pope-9/8/2005
281>>You're not suggesting that Lehman knew of the offering two days ago,tuck-9/8/2005
280You're not suggesting that Lehman knew of the offering two days ago, are youtom pope-9/8/2005
279NPSP jumps rather desperately at a Lehman upgrade two days ago -- which added 20tuck-9/8/2005
278SSB: NPSP: NEJM Article Weighs in on Combo & Sequential Osteo Therapies mopgcw-8/23/2005
277NPS Pharmaceuticals Files $200M Mixed Securities Shelf DOW JONES NEWSWIRES Augumopgcw-8/23/2005
276[Teduglutide improves intestinal function in short bowel syndrome patients ] &gtuck-8/18/2005
275>>SALT LAKE CITY, Aug. 18 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Ituck-8/18/2005
274A similar view from Morgan Stanley, courtesy of Forbes.com: >>NPS Pharma tuck-8/10/2005
273A little help from 2-year results from the PaTH study: >>SALT LAKE CITY, tuck-8/10/2005
272Merrill NPS Pharmaceuticals Inc.  Earnings Analysis; Price Objective Change; Ltom pope-7/27/2005
271>>Credit Suisse First Boston reiterated an "outperform" rating atuck-7/12/2005
270>>SALT LAKE CITY, July 11 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Ituck-7/11/2005
269[Oxadiazoles as modulators of mGluRs (mGluR5)] v3.espacenet.com You won't tuck-6/28/2005
268Last week, Hunter actually exercised some options for $8.5 that were to expire ttuck-6/17/2005
267From what little I know of Elise Wang, she seems very thorough and well informedtom pope-5/11/2005
266Apparently Elise was voted a great analyst or something in Forbes recently. I mmopgcw-5/11/2005
265NPS Pharmaceuticals Reports First Quarter 2005 Operating Results Tuesday May 10,mopgcw-5/10/2005
264SSB: NPSP: Additional Preos TOP Study Analyses Support Previous Findings mopgcw-4/13/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News